Agios Q3: Revenue $55.4M, Loss Narrows to $1.09/Share, $907M Cash
AGIO sits 29% above its 52-week low of $22.24 on light trading volume (0.1× avg).
Summary
Agios posted Q3 product revenue of $55.4 million, up from $12.9 million, and cut its quarterly net loss to $65.0 million, with $907.0 million in cash. The sickle cell PDUFA date has moved to February 1, 2027, and a generic challenge to PYRUKYND patents is in litigation.
Key Events · Earnings and Guidance · AGIO
-
Q3 Revenue Quadruples on AQVESME
Product revenue reached $55.4 million in Q3 2026 versus $12.9 million a year earlier, with U.S. sales of $48.7 million and rest-of-world $6.6 million. Nine-month revenue was $120.9 million versus $34.1 million.
-
Quarterly Loss Narrows to $1.09/Share
Net loss fell to $65.0 million, or $1.09 per share, from $103.4 million, or $1.78 per share. SG&A rose to $56.5 million from $41.3 million on launch spend, partly offset by R&D falling to $73.5 million from $86.8 million.
-
Sickle Cell PDUFA Pushed to February 2027
The FDA extended the mitapivat PDUFA goal date from November 1, 2026 to February 1, 2027 after Agios responded to an information request on whether a REMS is needed, which counted as a major amendment.
-
$907M Cash Covers Three-Plus Years
Cash, cash equivalents and marketable securities were $907.0 million at September 30, 2026, against $235.5 million of nine-month operating cash burn, down from $276.8 million a year earlier.
Analysis · AGIO · Life Sciences
The AQVESME launch is now converting into real revenue: product sales of $55.4 million more than quadrupled from $12.9 million a year ago, and the net loss narrowed to $65.0 million from $103.4 million. Against that, the sickle cell launch that was supposed to be the next leg of growth slipped — the FDA moved the mitapivat PDUFA date from November 1, 2026 to February 1, 2027 after Agios answered a REMS question, pushing the decision past today's date. With $907.0 million in cash against $235.5 million of nine-month operating burn, runway stands at roughly three-plus years at the current pace, so there is no near-term financing pressure. The offsetting risk is legal: Annora's Paragraph IV challenge to the PYRUKYND patents is in litigation, with an FDA approval stay running to at least August 17, 2029, while the composition-of-matter patent holds to 2035.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AGIO was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $22.24 to $46.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.